Peptide Therapy: The Evidence, the Risks and the Regulatory Landscape in Canada

Peptide therapy is attracting serious clinical interest, but the gap between preclinical promise and human evidence remains wide, and Canada’s regulatory landscape adds further complexity. Advance your ability to evaluate peptide interventions with the rigour they require. Source practical tips to:

• Distinguish what clinical and preclinical evidence actually exists from what remains theoretical or commercially overstated
• Identify what is currently available in Canada and where safety, dosing and regulatory considerations demand caution
• Adopt a responsible framework for evaluating peptide therapy as a practitioner or informed consumer

Achieve clarity on peptide therapy, and make decisions grounded in evidence, not enthusiasm